IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Clinical Trials
277
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (166 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- Biological: IPN01203
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 102
- Registration Number
- NCT07213830
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 102
- Registration Number
- NCT07213817
A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain
- Conditions
- PFIC - Progressive Familial Intrahepatic Cholestasis
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT07191704
A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 10
- Registration Number
- NCT07185919
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT07049887
- Locations
- 🇺🇸
Arizona Liver Center, Chandler, Arizona, United States
🇺🇸University of Miami School of Medicine, Center for Liver Diseases, Miami, Florida, United States
🇺🇸UT Southwestern Medical Center, Department of Internal Medicine, Digestive and Liver Diseases, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 56
- Next
News
Ipsen's IPN10200 Shows Superior Long-Term Efficacy in Phase II Glabellar Lines Trial
Ipsen's internally developed IPN10200 demonstrated statistically significant improvement in glabellar lines at Week 4 versus placebo in the Phase II LANTIC trial.
Ipsen's Bylvay Receives Japanese Approval for Rare Liver Disease PFIC, Offering First Non-Surgical Treatment Option
Japan's Ministry of Health, Labour and Welfare has approved Bylvay (odevixibat) as the first once-daily ileal bile acid transport inhibitor for treating pruritus in progressive familial intrahepatic cholestasis patients.
Parabilis Medicines Appoints Fawzi Benzaghou as Chief Medical Officer to Advance "Undruggable" Cancer Targets
Parabilis Medicines has appointed Fawzi Benzaghou, M.D., as Chief Medical Officer to lead clinical and regulatory strategy for its pipeline targeting historically "undruggable" cancer proteins.
Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders
Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.
Day One Biopharmaceuticals Reports 310% Revenue Surge for Pediatric Cancer Drug OJEMDA
Day One Biopharmaceuticals reported OJEMDA net product revenue of $33.6 million in Q2 2025, representing a 310% year-over-year increase driven by expanding adoption among pediatric oncologists.
IRIC and Ipsen Initiate Phase 1 Trial of RAF Inhibitor IPN01195 for Solid Tumors
IRIC and IRICoR announced the start of a Phase 1 clinical trial for IPN01195, a RAF inhibitor small molecule therapy for solid tumors licensed to Ipsen in July 2025.
NAPOLI 3 Post-Hoc Analysis Identifies Characteristics Associated with Long-Term Survival in Metastatic Pancreatic Cancer
A post-hoc analysis of the Phase III NAPOLI 3 trial identified characteristics associated with long-term survival in metastatic pancreatic adenocarcinoma patients treated with the NALIRIFOX regimen.
World ADC San Diego Conference Highlights Growing Industry Focus on Antibody-Drug Conjugates
The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.
Liver Cirrhosis Pipeline Shows Strong Growth with 30+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ liver cirrhosis therapies, with promising candidates like Rezdiffra, efruxifermin, and belapectin showing significant clinical progress.
GENFIT Reports Strong 2024 Financial Results with First Commercial Revenues from Iqirvo®
GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.